aap Implantate AG, a medical technology company listed on the Frankfurt stock exchange and active in biomaterials, fracture healing and joint replacement, achieved in the first three months of fiscal 2008 sales growth of 36% to EUR 8.0 million (previous year: EUR 5.9 million) and an operating result of EUR 0.7 million (previous year: -EUR 0.1 million).
The aap group of companies earned EUR 1.5 million in EBITDA (previous year: EUR 0.4 million) in the first quarter of 2008. Group EBIT totaled EUR 0.7 million (previous year: -EUR 0.1 million) and EBT EUR 0.5 million (previous year: -EUR 0.2 million). On total assets of EUR 69.4 million (previous year: EUR 68.0 million) the equity ratio was 63%.
Sales growth was due mainly to the very pleasing business trend in the Trauma & Orthopaedics division, which boosts sales to both international distribution partners and to OEM customers by 146% to EUR 3.7 million.
For the full year 2008 aap anticipates group sales growth at the previous year's level with sales up by at least 20% and an above-average earnings increase.
aap Implantate AG's full report for the first quarter of 2008 is available to you to download at www.aap.de.
The aap group of companies earned EUR 1.5 million in EBITDA (previous year: EUR 0.4 million) in the first quarter of 2008. Group EBIT totaled EUR 0.7 million (previous year: -EUR 0.1 million) and EBT EUR 0.5 million (previous year: -EUR 0.2 million). On total assets of EUR 69.4 million (previous year: EUR 68.0 million) the equity ratio was 63%.
Sales growth was due mainly to the very pleasing business trend in the Trauma & Orthopaedics division, which boosts sales to both international distribution partners and to OEM customers by 146% to EUR 3.7 million.
For the full year 2008 aap anticipates group sales growth at the previous year's level with sales up by at least 20% and an above-average earnings increase.
aap Implantate AG's full report for the first quarter of 2008 is available to you to download at www.aap.de.
